Gregory Krauss

EpiWatch, Inc. is a company founded by Nathan Crone and Gregory professors of neurology and epileptologists at the Johns Hopkins School of Medicine. The company is based in Baltimore, MD and uses technology licensed from Johns Hopkins. EpiWatch aims to lead the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition, and provide peace of mind for their loved ones. The company is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures. EpiWatch is leading the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition. Dean Papadopoulos has been the CEO of the company since 2020.

EpiWatch, Inc. is a company founded by Nathan Crone and Gregory professors of neurology and epileptologists at the Johns Hopkins School of Medicine. The company is based in Baltimore, MD and uses technology licensed from Johns Hopkins. EpiWatch aims to lead the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition, and provide peace of mind for their loved ones. The company is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures. EpiWatch is leading the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition. Dean Papadopoulos has been the CEO of the company since 2020.

EpiWatch, Inc. is a company founded by Nathan Crone and Gregory professors of neurology and epileptologists at the Johns Hopkins School of Medicine. The company is based in Baltimore, MD and uses technology licensed from Johns Hopkins. EpiWatch aims to lead the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition, and provide peace of mind for their loved ones. The company is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures. EpiWatch is leading the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition. Dean Papadopoulos has been the CEO of the company since 2020.

EpiWatch, Inc. is a company founded by Nathan Crone and Gregory professors of neurology and epileptologists at the Johns Hopkins School of Medicine. The company is based in Baltimore, MD and uses technology licensed from Johns Hopkins. EpiWatch aims to lead the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition, and provide peace of mind for their loved ones. The company is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures. EpiWatch is leading the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition. Dean Papadopoulos has been the CEO of the company since 2020.

EpiWatch, Inc. is a company founded by Nathan Crone and Gregory professors of neurology and epileptologists at the Johns Hopkins School of Medicine. The company is based in Baltimore, MD and uses technology licensed from Johns Hopkins. EpiWatch aims to lead the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition, and provide peace of mind for their loved ones. The company is initially developing a proprietary capability to detect and alert for potentially dangerous tonic-clonic (grand mal) seizures. EpiWatch is leading the digital transformation of epilepsy care by delivering innovative and integrated services that keep people with epilepsy safe, enable them, their caregivers, and their physicians to better manage their condition. Dean Papadopoulos has been the CEO of the company since 2020.